Allergic bronchopulmonary aspergillosis (ABPA) an IgE mediated disease?

Respiratory Medicine CME

Volumn 4, Issue 1, 2011, Pages 33-34

  Schulze, Johannes ^a   Zissler, Ulrich ^a   Christmann, Martin ^a   Rosewich, Martin ^a   Zielen, Stefan ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Allergic bronchopulmonary aspergillosis; Bronchial provocation; Cystic fibrosis; Omalizumab

Indexed keywords

IMMUNOGLOBULIN E; ITRACONAZOLE; METHACHOLINE; OMALIZUMAB; PREDNISONE; STEROID;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALLERGIC REACTION; ARTICLE; ASPERGILLUS FUMIGATUS; ATELECTASIS; CASE REPORT; CHILD; CYSTIC FIBROSIS; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HUMAN; HYPOTHESIS; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROVOCATION TEST; STEROID THERAPY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 79955529745     PISSN: 17550017     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmedc.2009.12.004     Document Type: Article

References (14)

1. Knutsen A.P., Bellone C., Kauffman H. Immunopathogenesis of allergic bronchopulmonary aspergillosis in cystic fibrosis. J Cyst Fibros 2002, 1:76-89.
2. Greenberger P.A. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002, 110:685-692.
3. Van der Ent C.K., Hoekstra H., Rijkers G.T. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007, 62:276-277.
4. Zirbes J.E., Milla C.A. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008, 43:607-610.
5. Kanu A., Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (Omalizumab). Pediatr Pulmonol 2008, 43:1249-1251.
6. Schulze J., Rosewich M., Riemer C., et al. Methacholine challenge - comparison of an ATS protocol to a new rapid single concentration technique. Respir Med 2009, 103:1898-1903.
7. Morice A.H., Kastelik J.A., Aziz I. Montelukast sodium in cystic fibrosis. Thorax 2001, 56:244-245.
8. Rosewich M., Rose M.A., Eickmeier O., et al. Montelukast as add-on therapy to beta-agonists and late airway response. Eur Respir J 2007, 30:56-61.
9. ATS/ERS task force: standardisation of spirometry. Eur Respir J 2005, 26:319-338.
10. Lieb A, Christmann M, Rosewich M, et al. Time course of the protective effects of omalizumab. Abstract at the EAACI; 2009.
11. Hartl D., Latzin P., Zissel G., et al. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med 2006, 173:1370-1376.
12. Humbert M., Beasley R., Ayres J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
13. Steiss J.O., Strohner P., Zimmer K.P., et al. Reduction of the total IgE level by omalizumab in children and adolescents. J Asthma 2008, 45:233-236.
14. Zielen S, Lieb A, De Monchy J, et al. Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels. Abstract at the ERS; 2009.